This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Bristol-Myers Squibb Pharmaceuticals.
Reference
Batteson R, et al. Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. PharmacoEconomics-Open : 5 Oct 2019. Available from: URL: https://doi.org/10.1007/s41669-019-00181-y
Rights and permissions
About this article
Cite this article
Modelling survival for adjuvant nivolumab in stage III/IV melanoma. PharmacoEcon Outcomes News 839, 28 (2019). https://doi.org/10.1007/s40274-019-6309-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6309-4